YM BioSciences partner Oncoscience AG reports update of pediatric brain cancer data
Nimotuzumab (Theraloc;TheraCIM h-R3) Phase II results awarded best poster prize at the 37th congress of the International Society of Paediatric Oncology.
Download: YM BioSciences pr9-27-05 (.pdf 20kB)